We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
News

Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University

Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
News

Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beckman Coulter, Inc. has announced that it has signed two agreements with Johns Hopkins University giving the company exclusive options to license cancer genomics intellectual property.

The first agreement covers 200 genes linked to breast and colon cancer, discovered in a landmark study published last year by researchers at Johns Hopkins Kimmel Cancer Center. Beckman Coulter Agencourt subsidiary's Genomic Services performed the sequencing for this study, which was co-authored by James Hartigan, an Agencourt project manager.

The second agreement covers sequencing services and options to license genomic intellectual property from current studies on six additional cancers.

"These unprecedented agreements put Beckman Coulter in a unique, leading-edge position in the molecular diagnostics field," commented Bruce Wallace, vice president of Beckman Coulter's Molecular Diagnostics Business Center.

"Beckman Coulter will have the exclusive option to license any of the genetic mutations discovered in these studies that have diagnostic potential. Given the leadership role Johns Hopkins is playing in cancer genetics, our relationship with them will help propel us to the forefront of this rapidly developing field," Wallace continued.

With these new agreements, Beckman Coulter will have first access to Johns Hopkins cancer study data. The company's molecular diagnostics assay group is already evaluating the breast and colon cancer genes.

"The success of our strategic plan is dependent in part on our development of a robust molecular diagnostics business," Wallace continued. "We are already in the process of moving our research genomics technologies into platforms for diagnostic use. Building content, or approved tests for that platform, from research such as the John Hopkins cancer genomics studies, will enhance our success."

Advertisement